Showing results (1-10 of 217) with videos related to
Sort By:
Pageof 22
Mediastinum (Hong Kong, China)|February 4, 2022
Targeted therapies for unresectable stage III non-small cell lung cancerJordi Remon, Lizza E L HendriksJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2025
De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?Jordi Remon, Martina Bortolot, Paolo Bironzo, et al.Expert Opinion on Investigational Drugs|March 10, 2017
Heat shock protein antagonists in early stage clinical trials for NSCLCLizza E L Hendriks, Anne-Marie C DingemansExpert Review of Anticancer Therapy|December 29, 2018
Prospects of targeted and immune therapies in SCLCLizza E L Hendriks, Jessica Menis, Martin ReckTranslational Lung Cancer Research|February 11, 2021
Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancerRoxana Reyes, Noemi ReguartFuture Oncology (London, England)|January 29, 2015
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitorsNoemi Reguart, Jordi RemonCancer Treatment Reviews|July 20, 2025
De-escalation strategies with targeted therapies in non-small cell lung cancerMartina Bortolot, Jordi Remon, Paolo Bironzo, et al.Translational Lung Cancer Research|July 23, 2021
Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?Lizza E L Hendriks, Jordi Remon, Jessica Menis, et al.Oncotargets and Therapy|August 9, 2020
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in ContextSneha Gullapalli, Jordi Remon, Lizza E L Hendriks, et al.Cancer Treatment Reviews|June 26, 2021
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challengesKaushal Parikh, Lizza E L Hendriks, Paolo Bironzo, et al.Pageof 22